Division of Breast and Thyroid Gland Surgery, Fukuyama City Hospital, Hiroshima, Japan
Division of Breast and Thyroid Gland Surgery, Fukuyama City Hospital, Hiroshima, Japan.
Anticancer Res. 2021 Jun;41(6):3109-3119. doi: 10.21873/anticanres.15095.
BACKGROUND/AIM: We investigated the usefulness of dynamic changes in absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR) during eribulin therapy as predictive markers for survival benefit including post-progression survival (PPS).
We retrospectively investigated 94 advanced breast cancer (ABC) patients who underwent eribulin therapy between July 2011 and June 2020.
The multivariate analysis showed that high baseline ALC and low NLR were independent predictive markers for overall survival (OS) (p=0.007 and p=0.011, respectively) and PPS (p=0.005 and p=0.007, respectively). Dynamic changes in ALC were also associated with OS and PPS (p=0.015, and p=0.026, respectively) and were an independent predictive marker for PPS (p=0.021).
Baseline ALC and NLR and dynamic changes in ALC during eribulin therapy were significantly associated with survival benefit including PPS for patients with ABC.
背景/目的：我们研究了艾立布林治疗期间绝对淋巴细胞计数（ALC）和中性粒细胞与淋巴细胞比值（NLR）的动态变化作为生存获益的预测标志物的有用性，包括进展后生存（PPS）。
我们回顾性调查了 94 名 2011 年 7 月至 2020 年 6 月期间接受艾立布林治疗的晚期乳腺癌（ABC）患者。
多变量分析显示，基线 ALC 高和 NLR 低是总生存（OS）和 PPS 的独立预测标志物（p=0.007 和 p=0.011）。ALC 的动态变化也与 OS 和 PPS 相关（p=0.015 和 p=0.026），并且是 PPS 的独立预测标志物（p=0.021）。
基线 ALC 和 NLR 以及艾立布林治疗期间 ALC 的动态变化与 ABC 患者的生存获益包括 PPS 显著相关。
